Brief: Outlook Therapeutics Says FDA Finds Substantial Evidence Of Effectiveness For Lytenava In nAMD
26/05/2026 12:08
BRIEF-Outlook Therapeutics Says FDA Finds Substantial Evidence Of Effectiveness For Lytenava In nAMD May 26 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS INC - FDA FINDS SUBSTANTIAL EVIDENCE OF EFFECTIVENESS FOR LYTENAVA IN NAMD
OUTLOOK THERAPEUTICS INC - TO RESUBMIT ONS-5010/LYTENAVA BLA IN JUNE 2026
OUTLOOK THERAPEUTICS INC - FDA GRANTS APPEAL FOR OUTLOOK THERAPEUTICS' ONS-5010/LYTENAVA
Source text: ID:nGNX54XPtF
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce